Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
PainChek LtdTelephone
61.8.9388.8290
Address
Suite 401 35 Lime Street Sydney, New South Wales (NSW) 2000
Description
PainChek Ltd. engages in the development and commercialization of mobile medical device applications. The company was founded on August 27, 2010 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.02 - 0.04
Trade Value (12mth)
AU$7,402.00
1 week
0%
1 month
-5.7%
YTD
-26.65%
1 year
-22.34%
All time high
0.43
EPS 3 yr Growth
3.70%
EBITDA Margin
-356.30%
Operating Cashflow
-$7m
Free Cash Flow Return
-727.90%
ROIC
-848.40%
Interest Coverage
N/A
Quick Ratio
1.40
Shares on Issue (Fully Dilluted)
1552m
HALO Sector
Technology
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
19 December 24 |
Application for quotation of securities - PCK
×
Application for quotation of securities - PCK |
19 December 24 |
Notification regarding unquoted securities - PCK
×
Notification regarding unquoted securities - PCK |
16 December 24 |
PainChek completes Entitlement Offer raising AUD $5.1 m
×
PainChek completes Entitlement Offer raising AUD $5.1 m |
11 December 24 |
PainChek Implementations, Market and International Expansion
×
PainChek Implementations, Market and International Expansion |
02 December 24 |
PainChek Entitlement Offer Open
×
PainChek Entitlement Offer Open |
28 November 24 |
Results of Meeting
×
Results of Meeting |
27 November 24 |
PCK AGM watching the live feed
×
PCK AGM watching the live feed |
25 November 24 |
Underwritten Entitlement Offer to raise AUD $5.1million
×
Underwritten Entitlement Offer to raise AUD $5.1million |
25 November 24 |
Prospectus
×
Prospectus |
25 November 24 |
Proposed issue of securities - PCK
×
Proposed issue of securities - PCK |
21 November 24 |
Trading Halt
×
Trading Halt |
20 November 24 |
PCK submits application for Adult App FDA De Novo clearance
×
PCK submits application for Adult App FDA De Novo clearance |
19 November 24 |
Addendum to BESTMED reseller agreement announcement
×
Addendum to BESTMED reseller agreement announcement |
13 November 24 |
PCK expands market reach with BESTMED reseller agreement
×
PCK expands market reach with BESTMED reseller agreement |
30 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 October 24 |
Quarterly Investor Presentation
×
Quarterly Investor Presentation |
29 October 24 |
Positive study results pave way for PainChek FDA submission
×
Positive study results pave way for PainChek FDA submission |
28 October 24 |
Appendix 4C quarterly webinar - 11am AEDT 30 October 2024
×
Appendix 4C quarterly webinar - 11am AEDT 30 October 2024 |
25 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
04 October 24 |
Notification of cessation of securities - PCK
×
Notification of cessation of securities - PCK |
04 October 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
02 October 24 |
PainChek Adult app FDA De Novo submission update
×
PainChek Adult app FDA De Novo submission update |
02 October 24 |
Application for quotation of securities - PCK
×
Application for quotation of securities - PCK |
30 September 24 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 September 24 |
Corporate Governance Statement & Appendix 4G 2024
×
Corporate Governance Statement & Appendix 4G 2024 |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.